A Long-Term Observational Study of the Safety of Ublituximab Patients with Relapsing Multiple Sclerosis in a Real-World Setting (ENLIGHTEN) First published 05/06/2025 Last updated 28/01/2026 EU PAS number:EUPAS1000000611 Study Ongoing